Cas: 134678-17-4 Lamivudine powder
| product name |
Lamivudine |
| cas number |
134678-17-4 |
| apperance |
White powder |
| Density |
1.7±0.1 g/cm3 |
| MF |
C8H11N3O3S |
| MW |
229.256 |
Lamivudine, also known as 3-TC, is a nucleoside analogue and antiviral drug. It is a white or off-white crystalline powder. It is soluble in water and slightly soluble in methanol. It can synthesize and extend the viral DNA chain. There is a competitive inhibitory effect.
Indications
Chronic hepatitis B caused by hepatitis B and hepatitis B virus replication.
[Patient's choice] 1. Suitable for treatment of chronic hepatitis B; according to the national viral hepatitis prevention and treatment plan, the diagnosis of chronic hepatitis B is not limited to gender, age 16 or older, and meets the following criteria. · HBeAg positive, HBV DNA positive (HBV DNA positive refers to dot blot method, not PCR positive, HBV DNA quantitative determination can be done if conditions permit. Where there is no condition to detect HBV DNA, HBeAg positive shall prevail). · HBeAg-negative, anti-HBe-positive, and HBV DNA-positive are also suitable for treatment in consideration of pre-C region mutations. · ALT is higher than normal and bilirubin is lower than 50μmol/L (3.0mg/dL). 2. Not suitable for treatment targets · Autoimmune liver disease. ·Inherited liver diseases: such as hepatolenticular degeneration, Wilson disease, hemochromatosis, alpha antitrypsin deficiency, etc. ·Bone marrow suppression: hemoglobin <10g/L, white blood cells <4x109/L, platelets <80x109/L (So far, lamivudine has not been found to have bone marrow suppression in clinical studies. For patients with bone marrow suppression tendency, strictly follow Doctor's order). · Have obvious heart, brain, nerve, mental illness and unstable diabetes. ·Pregnant women.
Audited Supplier 
){kind=link}
){kind=link}